DHA enhances the noradrenaline release by SH-SY5Y cells.
Polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA) and arachidonic acid (AA), are the main components of the phospholipids, in cerebral membranes. A dietary-induced cerebral DHA deficit results in altered behaviour and neurotransmission in rodents. To determine whether PUFA were acting on the neurotransmitter release machinery, we measured the release of [(3)H]-noradrenaline (NA) from SH-SY5Y neuroblastoma cells with modified PUFA membrane contents and from cells incubated with medium containing high DHA or AA. The membranes of cells incubated with 70 microM DHA for 3 days had 7.6-times more DHA in their ethanolamine glycerophospholipids, while the membranes of cells incubated with AA had 40% less. Incorporation of DHA enhanced basal [(3)H]-NA release (25%, p<0.05), but not KCl-evoked [(3)H]-NA release. Brief incubation with DHA during vesicle mobilization also strongly increased [3H]-NA release. AA had no effect. The genes encoding for the calcium sensor synaptotagmin 1, and for the two SNARE complex proteins syntaxin 1A and synaptobrevin 1 were not affected by PUFA incorporation, as indicated by assays for specific mRNAs and proteins. Thus both a high membrane DHA content and free DHA in the medium enhance the release of [(3)H]-NA from SH-SY5Y cells. This suggests that brain membrane DHA influences exocytosis, which then regulates neurotransmission.
Mathieu
Géraldine
G
INRA, Unité de Nutrition et Régulation Lipidiques des Fonctions Cérébrales (NuRéLiCe), UR909, Domaine de Vilvert, Jouy en Josas, France.
Géraldine
Mathieu
M
Denis
Stéphanie
S
Stéphanie
Denis
D
Langelier
Bénédicte
B
Bénédicte
Langelier
L
Denis
Isabelle
I
Isabelle
Denis
D
Lavialle
Monique
M
Monique
Lavialle
L
Vancassel
Sylvie
S
Sylvie
Vancassel
V
D001921:Brain / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D004281:Docosahexaenoic Acids / Q000378:metabolism* / Q000494:pharmacology; D005089:Exocytosis / Q000187:drug effects / Q000502:physiology*; D020404:Glycerophospholipids / Q000378:metabolism; D006801:Humans; D008563:Membrane Lipids / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D013572:Synaptic Vesicles / Q000187:drug effects / Q000378:metabolism; D014316:Tritium; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D020404:Glycerophospholipids; D008563:Membrane Lipids; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D014316:Tritium; D004281:Docosahexaenoic Acids; D009638:Norepinephrine